COVID-19 Breaking News
-
GSK Supports Manufacture of Novavax’ COVID-19 Vaccine
Tim Wright, Editor, Contract Pharma || 03.31.21
GSK will provide fill and finish manufacturing capacity for up to 60 million doses at its Barnard Castle facility.
-
CureVac, Celonic Enter COVID-19 Vax Mfg. Pact
Kristin Brooks || 03.30.21
Celonic is prepared to manufacture more than 100 million doses of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV, per year at Heidelberg facility.
-
Advanced Analytics Advancing Development of Genetic Vaccines
Kristin Brooks, Managing Editor, Contract Pharma || 03.29.21
Leveraging innovative advanced analytical technologies to ensure regulatory compliance in the development and production of novel vaccines.
-
Jubilant, Novavax Enter COVID-19 Vaccine Partnership
Tim Wright, Editor, Contract Pharma || 03.29.21
Jubilant to provide fill-finish manufacturing services for the production of COVID-19 vaccine candidate NVX-CoV2373.
-
EMA Approves BioNTech's COVID Vax Production at Marburg Site
Kristin Brooks || 03.26.21
Largest mRNA vaccine manufacturing site in Europe has annual production capacity of up to one billion doses of its COVID-19 vaccine.
-
CyanVac and Exothera Enter COVID-19 Vaccine Partnership
Tim Wright, Editor, Contract Pharma || 03.25.21
CDMO Exothera selected for the development and GMP manufacturing of intranasal vaccine candidate for Phase III clinical trial is Europe and the U.S.
-
RDIF & Stelis Enter Covid-19 Vaccine Supply Deal
Tim Wright, Editor, Contract Pharma || 03.19.21
Partner to supply 200 million doses of the Sputnik V vaccine.
-
Catalent Expands Partnership with J&J
Tim Wright, Editor, Contract Pharma || 03.17.21
To significantly increase capacity for sterile manufacturing and packaging of COVID-19 vaccine in Italy.
-
Cytocom Gets FDA Clearance for Phase II Trial of COVID Immune Therapy
Kristin Brooks || 03.16.21
Phase 2 clinical trial to evaluate the safety and efficacy of CYTO-205 as a treatment to slow or halt the progression of SARS-CoV-2.
-
Tevogen Bio, BioCentriq Partner for COVID T-cell Therapy
Kristin Brooks || 03.16.21
NJ-based cell and gene therapy development and manufacturing center to support clinical manufacturing of Tevogen’s investigational COVID-19 treatment.
-
Takeda and IDT Support Manufacturing of J&J’s COVID-19 Vaccine
Tim Wright, Editor, Contract Pharma || 03.15.21
Will make manufacturing capacity available at IDT’s facilities in Germany to manufacture the single-shot COVID-19 vaccine.
-
Maravai Expands CDMO Capabilities Through TriLink Biotechnologies
Tim Wright, Editor, Contract Pharma || 03.15.21
Offers end-to-end mRNA production with the launch of TriLink's plasmid DNA manufacturing services.
-
BioVaxys, Wuxi Biologics Enter Bioproduction Agreement
Tim Wright, Editor, Contract Pharma || 03.15.21
To synthesize proteins for SARS-CoV-2 vaccine and COVID-T immunodiagnostic programs.
-
Novavax Confirms Efficacy Against Original and Variant COVID-19 Strains
Kristin Brooks || 03.12.21
Final analysis of NVX–CoV2373 in UK trial confirms 96% efficacy against original strain of COVID-19 and 86.3% against the B.1.1.7 variant.
-
Altimmune, Lonza Expand AdCOVID Manufacturing Pact
Kristin Brooks || 03.12.21
Lonza to commission a dedicated suite for clinical and commercial supply of Altimmune’s COVID-19 vaccine candidate at its Houston facility.
-
Lilly's COVID Therapy Boasts Robust New Results
Kristin Brooks || 03.10.21
Phase 3 trial data shows bamlanivimab and etesevimab reduces the risk of COVID-related hospitalization and death by 87%.
-
Jubilant HollisterStier, Lilly Enter Bamlanivimab Mfg. Pact
03.09.21
COVID-19 therapy Bamlanivimab will be manufactured at Jubilant HollisterStier's Spokane, WA facility.
-
Baxter Biopharma Enters Sterile Manufacturing Agreement for Novavax’ COVID-19 Vaccine
Tim Wright, Editor, Contract Pharma || 03.09.21
Manufacturing to take place at Baxter’s state-of-the-art Halle/Westfalen, Germany facility.
-
Data Management Trends
Deepu Joseph, Global Head & VP of Clinical Data Management || 03.05.21
Pandemic-fueled patient centricity is creating new challenges and opportunities for data management teams.
-
CureVac, Novartis Ink COVID Vax Mfg. Pact
Kristin Brooks || 03.04.21
Novartis to manufacture the mRNA and bulk drug product of the CVnCoV vaccine for up to 50 million doses by the end of 2021.
